Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 52 Carcinoma, Renal Cell 47 Neoplasm Metastasis 24 Neoplasms 18 Kidney Neoplasms 18 Neuroendocrine Tumors 17 Carcinoma, Non-Small-Cell Lung 13 Tuberous Sclerosis 12 Stomach Neoplasms 12 Lymphoma, Mantle-Cell 12 Lymphoma, Large B-Cell, Diffuse 11 Recurrence 10 Prostatic Neoplasms 10 Lymphoma 10 Hodgkin Disease 10 Glioblastoma 10 Colorectal Neoplasms 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Brain Neoplasms 9 Lymphoma, Follicular 8 Lung Neoplasms 8 Leukemia, Lymphocytic, Chronic, B-Cell 8 Carcinoma 8 Waldenstrom Macroglobulinemia 7 Triple Negative Breast Neoplasms 7 Sarcoma 7 Multiple Myeloma 7 Lymphoma, B-Cell, Marginal Zone 7 Glioma 7 Central Nervous System Neoplasms 7

Interventions

tipifarnib 1 peginterferon alfa-2b 1 nilotinib 1 mirdametinib 1 binimetinib 1 Vincristine 1 Temozolomide 1 Sirolimus 1 Ranibizumab 1 Radiosurgery 1 Mn-PyC3A 1 Imatinib Mesylate 1 Everolimus 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neurofibroma × Everolimus × Clear all

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡